Claims
- 1. Pharmacologically active peptides of the formula:
- Tyr.sup.1 -X-A
- Tyr.sup.1 -X-A-Pro
- Tyr.sup.1 -X-A-Pro-B
- Tyr.sup.1 -X-A-Pro-B-Pro
- Tyr.sup.1 -X-A-Pro-B-Pro-C
- Tyr.sup.1 -X-A-Pro-B-Pro-C-Pro
- Tyr.sup.1 -X-A-Pro-B-Pro-C-Pro-D . . .
- wherein
- X is D-serine, D-arginine, D-methionine, D-lysine, D-phenylalanine, D-leucine, D-isoleucine, D-tryptophane or D-cystine;
- A is L-proline, L-tryosine or L-phenylalanine;
- B is L-proline, L-tryosine, or glycine;
- C is L-proline, L-tryosine, or L-isoleucine; and
- D is L-proline, L-tryosine, or L-asparagine.
- 2. Pharmacologically active peptides of the formula:
- Tyr.sup.1 -X-Phe
- Tyr.sup.1 -X-Phe-Pro
- Tyr.sup.1 -X-Phe-Pro-Gly
- Tyr.sup.1 -X-Phe-Pro-Gly-Pro
- Tyr.sup.1 -X-Phe-Pro-Gly-Pro-Ile
- Tyr.sup.1 -X-Phe-Pro-Gly-Pro-Ile-Pro
- Tyr.sup.1 -X-Phe-Pro-Gly-Pro-Ile-Pro-Asn
- wherein X represents D-serine, D-arginine, D-methionine, D-lysine, D-phenylalanine, D-leucine, D-isoleucine, D-tryptophane or D-cystine.
- 3. Pharmacologically active peptides according to claim 1 having the formula:
- Tyr-D-Ser-Phe-Pro-Gly-methylester.
- 4. Pharmacologically active peptides according to claim 1 having the formula:
- Tyr-D-Arg-Phe-Pro-Gly-methylester.
- 5. Pharmacologically active peptides according to claim 1 having the formula:
- Tyr-D-Met-Phe-Pro-Gly-methylester.
- 6. Pharmacologically active peptides according to claim 1 in which
- (a) an end-positioned L-tyrosine of the general formula ##STR10## is present wherein: R.sub.1 represents hydrogen or an alkyl group with 1 to 4 C-atoms,
- R.sub.2 represents hydrogen or together with R.sub.1 for an ethylene bond,
- R.sub.3 represents hydrogen, an alkyl group with 1 to 4 C-atoms or a R.sub.4 CO-group,
- R.sub.4 represents a saturated or unsaturated straight or branched chain alkyl residue with 1 to 17 C-atoms, a phenyl residue or a phenylalkyl residue with 7 to 12 C-atoms, in which the phenyl residues can be substituted by 1 to 2 substituents of the halogen series, alkyl with 1 to 4 C-atoms or alkoxy with 1 to 4 C-atoms,
- in which the R.sub.3 O group is in meta or para position to ##STR11## wherein W represents hydrogen, alkyl with 1 to 5 C-atoms, alkenyl with 3 to 5 C-atoms, cyclopropylmethyl, cyclobutylmethyl, R.sub.4 CO-, H-Arg-, H-Lys-, H-Phe, or H-Tyr-
- (b) an L-phenylalanine of the general formula: ##STR12## is present in which: R.sub.5 represents hydrogen or alkyl with 1 to 4 C-atoms,
- R.sub.6 represents hydrogen, fluorine, chlorine, bromine, nitro, alkyl with 1 to 4 C-atoms or alkoxy with 1 to 4 C-atoms, and Z represents 1 or 2,
- (c) the L-proline (at the positions of the amino acids 4, 6 or 8 of the peptide) of the general formula: ##STR13## is present, in which: R.sub.7 represents hydrogen, a hydroxy group, an alkyl group or alkoxy group with 1 to 4 C-atoms; an alkyl group or alkoxy group with 1 to 4 C-atoms is bonded to the nitrogen, and one to three keto groups are positioned on the ring,
- (d) the end-positioned, C-terminal amino acid is present as an amide or an ester (the C-terminal amino acid positioned to the right of Tyr in the peptide chain).
- 7. A pharmaceutical composition comprising a nontoxic pharmaceutically acceptable carrier and a therapeutically effective amount of peptide in the range of about 10 to 300 mg. according to claim 1 or an acid addition salt or a zinc, magnesium or cobalt complex of the peptide.
Priority Claims (1)
Number |
Date |
Country |
Kind |
2936099 |
Sep 1979 |
DEX |
|
Parent Case Info
This application is a continuation-in-part of copending application Ser. No. 258,617, filed as PCT DE80/00126, on Sept. 4, 1980, published as WO81/00712 on Mar. 19, 1981, .sctn.102(e) date filed Apr. 29, 1981, now U.S. Pat. No. 4,390,527 granted June 28, 1983.
US Referenced Citations (10)
Foreign Referenced Citations (1)
Number |
Date |
Country |
0025218 |
Mar 1981 |
EPX |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
258617 |
Apr 1981 |
|